Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | YAP1 | P46937 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706089 | 0.83 | SMN1; SMN2 (0.56) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23249889 | 0.83 | SMN1; SMN2 (0.58) | JAK2JAK1USP30SMN1; SMN2NPC1 | |
| SCHEMBL19123127 | 0.82 | JAK2 (0.53) | JAK2JAK1USP30SMN1; SMN2NPC1 | |
| SCHEMBL27141260 | 0.82 | JAK2 (0.51) | JAK2JAK1USP30SMN1; SMN2NPC1 | |
| SCHEMBL31697910 | 0.82 | SMN1; SMN2 (0.52) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27140943 | 0.82 | SMN1; SMN2 (0.52) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL18921640 | 0.81 | SMN1; SMN2 (0.56) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30602886 | 0.81 | SMN1; SMN2 (0.53) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30179036 | 0.81 | SMN1; SMN2 (0.53) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26705305 | 0.81 | SMN1; SMN2 (0.53) | JAK2JAK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884099-B2 | such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections | CUMBRE IP VENTURES, L.P. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090143373-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143373-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | NQO2, SDHA, QPCT | JAK2 3748/4885JAK1 4304/4885USP30 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.